The Food and Drug Administration (FDA) is considering stopping a safety study involving thousands of patients taking GlaxoSmithKline PLC’s Avandia according to the Wall Street Journal. Avandia has been linked to an increased risk of heart attack. If the trial is stopped, the FDA will also consider asking Glaxo to stop selling the drug, a decision that could also determine whether the drug stays on the U.S. market.
No decision on the trial (called TIDE) has been made yet, and according to the WSJ won’t be until after a July meeting about the drug.
